HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
ABCL
AbCellera Biologics Inc
Healthcare Biotechnology · British Columbia, Canada · Reports in usd
Market Cap: $1.57B
Market Cap
$1.57B
Enterprise Val
$1.15B
P/E Ratio
-10.71
P/B Ratio
1.62
Trailing PEG (1Y)
0.15
As Of
May 7, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value$966.9M
Gross Margin100.00%
Profit Margin100.00%
Return on Equity-14.79%
Return on Assets-10.73%
Current Ratio11.32
Debt/Equity0.14
LT Debt/Equity0.14
Revenue Per Share0.15

Income Statement

Dec 31, 2025
Revenue$44.9M
Cost of Revenue$0.00
Gross Profit$44.9M
R&D$50.1M
SG&A$17.2M
Operating Expenses$73.4M
Operating Income-$28.6M
Interest Expense$0.00
Tax Expense-$10.6M
Net Income-$8.9M
EPS (Basic)$-0.03
EPS (Diluted)$-0.03
EBIT-$19.5M
EBITDA-$11.6M
Consolidated Income-$8.9M
Non-Controlling Interests$0.00

Balance Sheet

Dec 31, 2025
Cash & Equivalents$153.5M
Accounts Receivable$58.3M
Inventory$0.00
Current Assets$728.2M
LT Investments$62.6M
Property, Plant & Equipment$428.0M
Intangibles$86.2M
Non-Current Assets$628.7M
Total Assets$1.36B
Accounts Payable$50.8M
Current Debt$0.00
Current Liabilities$64.3M
LT Debt$137.4M
Non-Current Liabilities$325.7M
Total Liabilities$390.0M
Total Debt$137.4M
Retained Earnings-$29.5M
Shareholder Equity$966.9M
Shares Outstanding299,335,048

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow-$34.7M
Investing Cash Flow$75.1M
Financing Cash Flow$4.1M
CapEx-$9.8M
Free Cash Flow-$44.6M
Depreciation & Amort.$7.9M
Stock-Based Comp$12.9M
Acquisitions / Disposals$33.3M
Investment Activity$37.7M
Debt Issued/Repaid$29.7M
Equity Issued/Repaid$0.00
Dividends Paid$0.00
Net Change in Cash$44.8M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h